Aerpio Pharmaceuticals, Inc. (ARPO) financial statements (2020 and earlier)

Company profile

Business Address 9987 CARVER ROAD
CINCINNATI, OH 45242
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments39434853636969
Cash and cash equivalents39434853636969
Prepaid expense0100100
Other current assets1101110
Total current assets:40454954647069
Noncurrent Assets
Operating lease, right-of-use asset00  
Property, plant and equipment0000000
Deposits noncurrent assets0000000
Other undisclosed noncurrent assets  01   
Total noncurrent assets:0111000
TOTAL ASSETS:40465055647070
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3334543
Accounts payable0111111
Accrued liabilities0001111
Employee-related liabilities1110211
Other undisclosed accounts payable and accrued liabilities2222211
Debt00     
Contract with customer, liability  19
Other undisclosed current liabilities  00   
Total current liabilities:34445422
Noncurrent Liabilities
Long-term debt and lease obligation00     
Operating lease, liability00  
Other undisclosed noncurrent liabilities  00   
Total noncurrent liabilities:0000   
Total liabilities:34445422
Stockholders' equity
Stockholders' equity attributable to parent37424651596748
Common stock0000000
Additional paid in capital179179179178178177170
Accumulated deficit(142)(138)(133)(127)(119)(110)(122)
Total stockholders' equity:37424651596748
TOTAL LIABILITIES AND EQUITY:40465055647070

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:    0191
Operating expenses(5)(5)(6)(9)(9)(8)(7)
Operating income (loss):(5)(5)(6)(9)(9)11(6)
Nonoperating income0000000
Net income (loss) available to common stockholders, diluted:(4)(5)(6)(8)(9)12(6)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(4)(5)(6)(8)(9)12(6)
Comprehensive income (loss), net of tax, attributable to parent:(4)(5)(6)(8)(9)12(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: